Cytokines in oncolytic virotherapy

Jonathan G. Pol; Samuel T. Workenhe; Prathyusha Konda; Shashi Gujar; Guido Kroemer

doi:10.1016/j.cytogfr.2020.10.007

Cytokines in oncolytic virotherapy

Jonathan G. Pol, Samuel T. Workenhe, Prathyusha Konda, Shashi Gujar, Guido Kroemer

Medicine

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

45 Citas (Scopus)

Resumen

Tumors represent a hostile environment for the effector cells of cancer immunosurveillance. Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly exposed and released by malignant entities and their stromal accomplices. As a consequence, executioners of antitumor immunity inefficiently navigate across cancer tissues and fail to eliminate malignant targets. By inducing immunogenic cancer cell death, oncolytic viruses profoundly reshape the tumor microenvironment. They trigger the local spread of danger signals and tumor-associated (as well as viral) antigens, thus attracting antigen-presenting cells, promoting the activation and expansion of lymphocytic populations, facilitating their infiltration in the tumor bed, and reinvigorating cytotoxic immune activity. The present review recapitulates key chemokines, growth factors and other cytokines that orchestrate this ballet of antitumoral leukocytes upon oncolytic virotherapy.

Idioma original	English
Páginas (desde-hasta)	4-27
Número de páginas	24
Publicación	Cytokine and Growth Factor Reviews
Volumen	56
DOI	https://doi.org/10.1016/j.cytogfr.2020.10.007
Estado	Published - dic. 2020

Nota bibliográfica

Funding Information:
JGP is supported by the SIRIC Cancer Research and Personalized Medicine (CARPEM) . GK is supported by the Ligue contre le Cancer (équipe labellisée) ; Agence National de la Recherche (ANR) – Projets blancs ; ANR under the frame of E-Rare-2 , the ERA-Net for Research on Rare Diseases ; Association pour la recherche sur le cancer (ARC) ; Cancéropôle Ile-de-France ; Chancellerie des universités de Paris (Legs Poix) , Fondation pour la Recherche Médicale (FRM) ; a donation by Elior ; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR) ; Gustave Roussy Odyssea , the European Union Horizon 2020 Project Oncobiome ; Fondation Carrefour ; High-end Foreign Expert Program in China ( GDW20171100085 and GDW20181100051 ), Institut National du Cancer (INCa) ; Inserm (HTE) ; Institut Universitaire de France ; LeDucq Foundation ; the LabEx Immuno-Oncology ; the RHU Torino Lumière ; the Seerave Foundation ; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) ; and the SIRIC Cancer Research and Personalized Medicine (CARPEM) .

Publisher Copyright:
© 2020 The Author(s)

ASJC Scopus Subject Areas

Endocrinology, Diabetes and Metabolism
Immunology and Allergy
Immunology
General Biochemistry,Genetics and Molecular Biology

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/j.cytogfr.2020.10.007

Otros archivos y enlaces

Citar esto

@article{2fc19b1bf14a4eda9808ea7c8dd4520a,

title = "Cytokines in oncolytic virotherapy",

abstract = "Tumors represent a hostile environment for the effector cells of cancer immunosurveillance. Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly exposed and released by malignant entities and their stromal accomplices. As a consequence, executioners of antitumor immunity inefficiently navigate across cancer tissues and fail to eliminate malignant targets. By inducing immunogenic cancer cell death, oncolytic viruses profoundly reshape the tumor microenvironment. They trigger the local spread of danger signals and tumor-associated (as well as viral) antigens, thus attracting antigen-presenting cells, promoting the activation and expansion of lymphocytic populations, facilitating their infiltration in the tumor bed, and reinvigorating cytotoxic immune activity. The present review recapitulates key chemokines, growth factors and other cytokines that orchestrate this ballet of antitumoral leukocytes upon oncolytic virotherapy.",

author = "Pol, {Jonathan G.} and Workenhe, {Samuel T.} and Prathyusha Konda and Shashi Gujar and Guido Kroemer",

note = "Funding Information: JGP is supported by the SIRIC Cancer Research and Personalized Medicine (CARPEM) . GK is supported by the Ligue contre le Cancer ({\'e}quipe labellis{\'e}e) ; Agence National de la Recherche (ANR) – Projets blancs ; ANR under the frame of E-Rare-2 , the ERA-Net for Research on Rare Diseases ; Association pour la recherche sur le cancer (ARC) ; Canc{\'e}rop{\^o}le Ile-de-France ; Chancellerie des universit{\'e}s de Paris (Legs Poix) , Fondation pour la Recherche M{\'e}dicale (FRM) ; a donation by Elior ; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR) ; Gustave Roussy Odyssea , the European Union Horizon 2020 Project Oncobiome ; Fondation Carrefour ; High-end Foreign Expert Program in China ( GDW20171100085 and GDW20181100051 ), Institut National du Cancer (INCa) ; Inserm (HTE) ; Institut Universitaire de France ; LeDucq Foundation ; the LabEx Immuno-Oncology ; the RHU Torino Lumi{\`e}re ; the Seerave Foundation ; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) ; and the SIRIC Cancer Research and Personalized Medicine (CARPEM) . Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = dec,

doi = "10.1016/j.cytogfr.2020.10.007",

language = "English",

volume = "56",

pages = "4--27",

journal = "Cytokine and Growth Factor Reviews",

issn = "1359-6101",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Cytokines in oncolytic virotherapy

AU - Pol, Jonathan G.

AU - Workenhe, Samuel T.

AU - Konda, Prathyusha

AU - Gujar, Shashi

AU - Kroemer, Guido

N1 - Funding Information: JGP is supported by the SIRIC Cancer Research and Personalized Medicine (CARPEM) . GK is supported by the Ligue contre le Cancer (équipe labellisée) ; Agence National de la Recherche (ANR) – Projets blancs ; ANR under the frame of E-Rare-2 , the ERA-Net for Research on Rare Diseases ; Association pour la recherche sur le cancer (ARC) ; Cancéropôle Ile-de-France ; Chancellerie des universités de Paris (Legs Poix) , Fondation pour la Recherche Médicale (FRM) ; a donation by Elior ; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR) ; Gustave Roussy Odyssea , the European Union Horizon 2020 Project Oncobiome ; Fondation Carrefour ; High-end Foreign Expert Program in China ( GDW20171100085 and GDW20181100051 ), Institut National du Cancer (INCa) ; Inserm (HTE) ; Institut Universitaire de France ; LeDucq Foundation ; the LabEx Immuno-Oncology ; the RHU Torino Lumière ; the Seerave Foundation ; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) ; and the SIRIC Cancer Research and Personalized Medicine (CARPEM) . Publisher Copyright: © 2020 The Author(s)

PY - 2020/12

Y1 - 2020/12

N2 - Tumors represent a hostile environment for the effector cells of cancer immunosurveillance. Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly exposed and released by malignant entities and their stromal accomplices. As a consequence, executioners of antitumor immunity inefficiently navigate across cancer tissues and fail to eliminate malignant targets. By inducing immunogenic cancer cell death, oncolytic viruses profoundly reshape the tumor microenvironment. They trigger the local spread of danger signals and tumor-associated (as well as viral) antigens, thus attracting antigen-presenting cells, promoting the activation and expansion of lymphocytic populations, facilitating their infiltration in the tumor bed, and reinvigorating cytotoxic immune activity. The present review recapitulates key chemokines, growth factors and other cytokines that orchestrate this ballet of antitumoral leukocytes upon oncolytic virotherapy.

AB - Tumors represent a hostile environment for the effector cells of cancer immunosurveillance. Immunosuppressive receptors and soluble or membrane-bound ligands are abundantly exposed and released by malignant entities and their stromal accomplices. As a consequence, executioners of antitumor immunity inefficiently navigate across cancer tissues and fail to eliminate malignant targets. By inducing immunogenic cancer cell death, oncolytic viruses profoundly reshape the tumor microenvironment. They trigger the local spread of danger signals and tumor-associated (as well as viral) antigens, thus attracting antigen-presenting cells, promoting the activation and expansion of lymphocytic populations, facilitating their infiltration in the tumor bed, and reinvigorating cytotoxic immune activity. The present review recapitulates key chemokines, growth factors and other cytokines that orchestrate this ballet of antitumoral leukocytes upon oncolytic virotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85096389915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096389915&partnerID=8YFLogxK

U2 - 10.1016/j.cytogfr.2020.10.007

DO - 10.1016/j.cytogfr.2020.10.007

M3 - Review article

C2 - 33183957

AN - SCOPUS:85096389915

SN - 1359-6101

VL - 56

SP - 4

EP - 27

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

ER -

Cytokines in oncolytic virotherapy

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto